{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:39:37Z","timestamp":1791725977673,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.bbr.2021.113168","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T03:33:53Z","timestamp":1612928033000},"page":"113168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies"],"prefix":"10.1016","volume":"404","author":[{"given":"Dainora","family":"Cepaityte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-4120","authenticated-orcid":false,"given":"Georgios","family":"Papazisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2021.113168_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euroneuro.2020.03.022","article-title":"The association between receptor binding affinity and metabolic side effect profile of antipsychotics and major cardio- and cerebrovascular events: a case\/non-case study using VigiBase","volume":"35","author":"Aguiar","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/JCP.0b013e3181c8273d","article-title":"Priapism associated with antipsychotics: role of \u03b11 adrenoceptor affinity","volume":"30","author":"Andersohn","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2012.10.009","article-title":"Antipsychotics and seizures: higher risk with atypicals?","volume":"22","author":"Lertxundi","year":"2013","journal-title":"Seizure."},{"key":"10.1016\/j.bbr.2021.113168_bib0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2165\/11532560-000000000-00000","article-title":"Hyponatraemia as an adverse drug reaction of antipsychotic drugs","volume":"33","author":"Mannesse","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11096-011-9541-y","article-title":"Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case","volume":"33","author":"Meyer-Massetti","year":"2011","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.bbr.2021.113168_bib0030","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.euroneuro.2015.07.010","article-title":"Role of serotonin 5-HT 2C and histamine H 1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase","volume":"25","author":"Montastruc","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep26375","article-title":"Prevention of antipsychotic-induced hyperglycaemia by Vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism","volume":"6","author":"Nagashima","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2021.113168_bib0040","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bcp.13145","article-title":"An original pharmacoepidemiological\u2013pharmacodynamic method: application to antipsychotic-induced movement disorders","volume":"83","author":"Nguyen","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40264-013-0032-z","article-title":"Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse event reporting system database","volume":"36","author":"Poluzzi","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40264-020-00928-1","article-title":"A disproportionality analysis of the adverse drug events associated with Lurasidone in paediatric patients using the US FDA adverse event reporting system (FAERS)","volume":"43","author":"Rees","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0055","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s40264-017-0560-z","article-title":"Signal of miscarriage with aripiprazole: a disproportionality analysis of the japanese adverse drug event report database","volume":"40","author":"Sakai","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/JCP.0000000000001198","article-title":"Reporting patterns of sialorrhea comparing users of clozapine to users of other antipsychotics: a disproportionality analysis using VigiBase","volume":"40","author":"Man","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/YIC.0000000000000146","article-title":"Risk excess of mortality and use of antipsychotics: a case-noncase study","volume":"32","author":"Arias","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0070","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1177\/1060028020913974","article-title":"Association between antipsychotics and osteoporosis based on real-world data","volume":"54","author":"Yokoyama","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bbr.2021.113168_bib0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.schres.2014.06.003","article-title":"Polycystic ovaries is a disproportionate signal in pharmacovigilance data mining of second generation antipsychotics","volume":"158","author":"Yum","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbr.2021.113168_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1574886313666181026100000","article-title":"Novel adverse events of Iloperidone: a disproportionality analysis in US food and drug administration adverse event reporting system (FAERS) database","volume":"14","author":"Subeesh","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.psychres.2018.09.014","article-title":"Antipsychotics and cardiovascular risk: a case\/non-case study","volume":"270","author":"Arias","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbr.2021.113168_bib0090","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/pds.5016","article-title":"Safety of clozapine use during pregnancy: analysis of international pharmacovigilance data","volume":"29","author":"Beex-Oosterhuis","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.9740\/mhc.2020.05.070","article-title":"Clozapine and hematologic adverse reactions: impact of the Risk Evaluation and Mitigation Strategy program","volume":"10","author":"Borrelli","year":"2020","journal-title":"Ment. Heal. Clin."},{"key":"10.1016\/j.bbr.2021.113168_bib0100","first-page":"1","article-title":"Haematologic malignancies associated with clozapine v. All other antipsychotic agents: a pharmacovigilance study in VigiBase\u00ae","author":"Chr\u00e9tien","year":"2020","journal-title":"Psychol. Med. (Paris)"},{"key":"10.1016\/j.bbr.2021.113168_bib0105","first-page":"263","article-title":"Venous thrombosis during olanzapine treatment: a complex association","volume":"76","author":"Dijkstra","year":"2018","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.bbr.2021.113168_bib0110","first-page":"1","article-title":"Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports","volume":"1","author":"Kato","year":"2015","journal-title":"J. Pharm. Heal. Care Sci."},{"key":"10.1016\/j.bbr.2021.113168_bib0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7150\/ijms.10453","article-title":"Antipsychotics-associated serious adverse events in children: an analysis of the faers database","volume":"12","author":"Kimura","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bbr.2021.113168_bib0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/cap.2011.0134","article-title":"Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis","volume":"22","author":"Star","year":"2012","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1089\/cap.2018.0139","article-title":"Reported adverse drug reactions in children and adolescents treated with antipsychotics","volume":"29","author":"Minjon","year":"2019","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0130","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.bbr.2021.113168_bib0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the japanese adverse drug event report database (JADER)","volume":"29","author":"Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pds.848","article-title":"Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole","volume":"12","author":"Moore","year":"2003","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0145","unstructured":"EudraVigilance | European Medicines Agency, (n.d.). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance (accessed December 28, 2019)."},{"key":"10.1016\/j.bbr.2021.113168_bib0150","doi-asserted-by":"crossref","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2021.113168_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/schbul\/sbz093","article-title":"Data from the world health organization\u2019s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions","volume":"46","author":"De Leon","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbr.2021.113168_bib0160","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bbr.2021.113168_bib0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie."},{"key":"10.1016\/j.bbr.2021.113168_bib0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection is spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0175","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/JCP.0000000000000814","article-title":"Is there a potential of misuse for quetiapine?","volume":"38","author":"Chiappini","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/YIC.0000000000000194","article-title":"Aripiprazole and impulse control disorders: Higher risk with the intramuscular depot formulation?","volume":"33","author":"Lertxundi","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/YIC.0000000000000247","article-title":"Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance)","volume":"34","author":"Lertxundi","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0190","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00228-002-0484-z","article-title":"Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs","volume":"58","author":"Bate","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0195","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.322.7296.1207","article-title":"Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study","volume":"322","author":"Coulter","year":"2001","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bbr.2021.113168_bib0200","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40263-017-0448-6","article-title":"Clozapine-induced gastrointestinal hypomotility: a 22-Year Bi-National pharmacovigilance study of serious or fatal \u2018Slow gut\u2019 reactions, and comparison with international drug safety advice","volume":"31","author":"Every-Palmer","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbr.2021.113168_bib0205","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bcp.13145","article-title":"An original pharmacoepidemiological\u2013pharmacodynamic method: application to antipsychotic-induced movement disorders","volume":"83","author":"Nguyen","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0210","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40264-016-0413-1","article-title":"Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition Bias: a disproportionality analysis using data from vigibase\u00ae","volume":"39","author":"Montastruc","year":"2016","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0215","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/cts.12543","article-title":"Association between serotonin syndrome and second-generation antipsychotics via pharmacological target-adverse event analysis","volume":"11","author":"Racz","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bbr.2021.113168_bib0220","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.26.6.748","article-title":"Atypical antipsychotics and pituitary tumors: a pharmacovigilance study","volume":"26","author":"Szarfman","year":"2006","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.bbr.2021.113168_bib0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10401230701844612","article-title":"Antipsychotics, glycemic disorders, and life-threatening diabetic events: a bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004)","volume":"20","author":"Dumouchel","year":"2008","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2021.113168_bib0230","article-title":"Comparison of quetiapine abuse and misuse reports to the FDA adverse event reporting system with other second-generation antipsychotics","volume":"13","author":"Evoy","year":"2019","journal-title":"Subst. Abus. Res. Treat."},{"key":"10.1016\/j.bbr.2021.113168_bib0235","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet."},{"key":"10.1016\/j.bbr.2021.113168_bib0240","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.bbr.2021.113168_bib0245","series-title":"Observational and Retrospective Study Using the WHO Pharmacovigilance Database","author":"Clozapine and Haematologic Malignancies","year":"2019"},{"key":"10.1016\/j.bbr.2021.113168_bib0250","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0255","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bbr.2021.113168_bib0260","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2168479017741112","article-title":"Sources of safety data and statistical strategies for design and analysis: postmarket surveillance","volume":"52","author":"Izem","year":"2018","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.bbr.2021.113168_bib0265","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the food and drug administration, J. Am","volume":"23","author":"Duggirala","year":"2016","journal-title":"Med. Informatics Assoc."},{"key":"10.1016\/j.bbr.2021.113168_bib0270","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0275","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/pds.3622","article-title":"Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database","volume":"23","author":"de Boissieu","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0280","article-title":"Existence of notoriety Bias in FDA adverse event reporting system database and its impact on signal strength","author":"Neha","year":"2019","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.bbr.2021.113168_bib0285","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and drug administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbr.2021.113168_bib0295","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2125.1999.00881.x","article-title":"Is reporting rate a good predictor of risks associated with drugs?","volume":"47","author":"Pierfitte","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113168_bib0300","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-3956(00)00032-7","article-title":"Effects of antipsychotic drugs on cytokine networks","volume":"34","author":"Pollm\u00e4cher","year":"2000","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.bbr.2021.113168_bib0305","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12888-020-02711-z","article-title":"Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database","volume":"20","author":"Revet","year":"2020","journal-title":"BMC Psychiatry"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432821000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432821000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:27:16Z","timestamp":1759066036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432821000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":61,"alternative-id":["S0166432821000553"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2021.113168","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2021.113168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113168"}}